Study Title
NeoPSMA: A Phase I/II, Open-label, Multi-center Study of Neoadjuvant Treatment With [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Adults With Prostate-specific Membrane Antigen (PSMA) Positive High-risk Localized Prostate Cancer (HRLPC) Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection
Study Details
Description:
The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate and lymph nodes present in the pelvis area. Lymph nodes are small structures near the prostate that help fight infections. These lymph nodes are removed during surgery because they are a site the disease can spread to.
Sponsor:
NovartisContacts:
Novartis Pharmaceuticalsnovartis.email@novartis.com
1-888-669-6682
Government Study Link:
NCT06881823 - Click here to see study onClinicalTrials.gov
Drug Details
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
Not yet provided. Contact Novartis Pharmaceuticals for more information.
1-888-669-6682
novartis.email@novartis.com